Clinical trials: Standard Therapy
Cardiovascular Diseases, Acute Coronary Syndrome
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke.
- Trial name
- PAPI-2 (NCT01452152)
- Testing
- clopidogrel, prasugrel
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Maryland, Baltimore
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 1 (NCT01510158)
- Testing
- Lesinurad, Allopurinol
- Where
- 165 sites in United States
- Volunteers
- 607 people
- Sponsor
- Ardea Biosciences, Inc.
Peripheral T Cell Lymphoma
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
- Trial name
- NCT03586999
- Testing
- Nivolumab, Etoposide, Prednisolone
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Melanoma
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202…
- Trial name
- NCT02723006
- Testing
- TAK-580, TAK-202, vedolizumab
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ovarian Cancer
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
- Trial name
- PemCiGem (NCT02608684)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Cedars-Sinai Medical Center
HIV Infections
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
The researchers are involved in a phase II, randomized, two-arm study, comparing the efficacy, safety, and tolerability of open-label ritonavir (RTV)-enhanced darunavir with Truvada to a 5-drug multi-class regimen including…
- Trial name
- NCT00525733
- Testing
- darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rockefeller University
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
The LUME-Lung3 study is in 2 parts: Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.
- Trial name
- NCT01346540
- Testing
- BIBF 1120
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Refractory Metastatic Gastric Cancer
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.
- Trial name
- NCT02500043
- Testing
- TAS-102
- Where
- 139 sites in United States, Belarus and 16 more
- Volunteers
- 507 people
- Sponsor
- Taiho Oncology, Inc.
Wounds
Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
The main purpose of this phase III clinical trial was to show safety and efficacy of Oleogel-S10 in accelerating the wound healing of Split-Thickness Skin Graft (STSG) donor sites.
- Trial name
- BSG-12 (NCT01807650)
- Testing
- Oleogel-S10, non-adhesive wound dressing, Non-adhesive wound dressing only
- Where
- 14 sites in France, Greece and 2 more
- Volunteers
- 112 people
- Sponsor
- Birken AG
Stage IV Pancreatic Cancer
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
The investigators recently completed a phase I study of intravenous ascorbic acid (IV AA) plus standard chemotherapy (gemcitabine and erlotinib) in patients with metastatic pancreatic cancer.
- Trial name
- NCT01555489
- Testing
- Ascorbic Acid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Jefferson University
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial studies the side effects and best dose of bortezomib when given together with daunorubicin and cytarabine and to see how well it works in treating older patients with previously untreated acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00742625
- Testing
- daunorubicin hydrochloride, cytarabine, bortezomib
- Where
- 22 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute…
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT02085408
- Testing
- Daunorubicin, Cytarabine, Clofarabine
- Where
- 269 sites in United States, India and 1 more
- Volunteers
- 727 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Acute Lung Injury
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
The purpose of this study is to test a treatment that tries to reduce the amount of fluid in the lungs of subjects with acute lung injury to see if this is helpful.
- Trial name
- HEAL (NCT00624650)
- Testing
- Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Oregon Health and Science University
Chemotherapy-induced Nausea and Vomiting
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
- Trial name
- CINV (NCT04817189)
- Testing
- NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
- Where
- 19 sites in China, Czechia and 5 more
- Volunteers
- 414 people
- Sponsor
- Helsinn Healthcare SA
ADHD
ADHD Treatment for Latino Families
The current pilot study aims to close the existing gap in our knowledge about effective psychosocial treatments for Latino families by providing preliminary data regarding the acceptability and efficacy of a culturally-modified…
- Trial name
- NCT02317692
- Testing
- Parent training
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Marquette University
Scar, Skin Scarring
Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment
Patients will be randomized either to receive standard daily dressing or hydrocolloid dressing using a randomization generator. After closing the wound with the sutures,the scar will be covered by a hydrocolloid dressing, which…
- Conditions
- Scar, Skin Scarring, Skin Cancer, Wound Heal
- Trial name
- NCT05618912
- Testing
- Hydrocolloid dressing, Petrolatum jelly dressing
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Indiana University
Breast Cancer, Stage IV Breast Cancer
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
RATIONALE: The primary tumor might be a source of re-seeding of distant sites and therefore elimination of this source of metastasizing cells by early local therapy may be of benefit.
- Trial name
- NCT01242800
- Testing
- palliative surgery, therapeutic conventional surgery, palliative radiation therapy
- Where
- 377 sites in United States, Canada and 3 more
- Volunteers
- 390 people
- Sponsor
- Eastern Cooperative Oncology Group